GnRH agonist + aromatase inhibitor combination

This page covers all GnRH agonist + aromatase inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GnRH receptor; aromatase (CYP19A1), CDK4/6 + Aromatase, Estrogen receptor alpha (ERα), CDK4/6, aromatase.

Targets

GnRH receptor; aromatase (CYP19A1) · CDK4/6 + Aromatase · Estrogen receptor alpha (ERα), CDK4/6, aromatase

Marketed (2)

• Ultra-Long GnRH Agonists + Letrozole · University of Palermo · Oncology; Gynecology
  Ultra-long GnRH agonists suppress gonadal hormone production while letrozole blocks aromatase to inhibit estrogen synthesis, creating a dual hormonal suppression strategy.
• Abemaciclib + Aromatase Inhibitor · Prof. Wolfgang Janni · Oncology
  Abemaciclib inhibits CDK4/6 to block cell cycle progression in hormone receptor-positive breast cancer, while the aromatase inhibitor reduces estrogen production to further suppress tumor growth.

Phase 3 pipeline (1)

• XZP-3287+ Letrozole/Anastrozole · Xuanzhu Biopharmaceutical Co., Ltd. · Oncology
  XZP-3287 combined with aromatase inhibitors (letrozole or anastrozole) blocks estrogen production to treat hormone receptor-positive breast cancer.

Patent intelligence

• aromatase inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates